Article Figures & Data
Figures
- FIGURE 1.
SUVmax in most intense tumor lesion per patient (A) and in all tumor lesions (B) at baseline, 2 wk, and 12 wk. Horizontal bars represent median values.
- FIGURE 2.
PET images 4 d after 89Zr-bevacizumab injection in patient with metastatic midgut carcinoid. (A) Coronal and axial images of low-dose CT and fusion images of PET. Low-dose CT shows increased tracer uptake in abdominal tumor lesion. (B) Coronal PET images at baseline, 2 wk, and 12 wk of everolimus treatment. Physiologic 89Zr-bevacizumab uptake is present in heart (blood pool), liver, spleen, and circulation. At baseline, increased 89Zr-bevacizumab uptake was found in tumor lesion located in ileocecal angle (arrows). Tumor uptake was 43% lower at 2 wk and 69% lower at 12 wk during everolimus treatment.
- FIGURE 3.
Waterfall plots of 10 patients with visualized tumor lesions at 89Zr-bevacizumab PET. (A) Maximum baseline SUVmax (blue bars) and percentage change in sum of target lesion diameters according to RECIST1.1 on CT after 6 mo (yellow bars). (B) ΔSUVmax at 12 wk of most intense tumor lesion at baseline (blue bars) and percentage change in sum of target lesion diameters according to RECIST1.1 on CT after 6 mo (yellow bars). * = patient is still on everolimus.
- FIGURE 4.
Graphs showing whole-blood everolimus levels after 2 wk and 12 wk of everolimus treatment (n = 11) (A) and serum VEGF-A levels measured at baseline and 12 wk of treatment (n = 13) (B). Horizontal bars represent median values. *P < 0.05.
Tables
Characteristic n Age (y) Median 60 Range 43–67 Sex Male 7 Female 7 Eastern Cooperative Oncology Group performance score 0 12 1 1 2 1 Localization of the primary tumor Lung 1 Pancreas 7 Duodenal bulb 1 Small bowel 3 Unknown 2 NET World Health Organization grading Grade 1 8 Grade 2 6 Peptide-producing NET Chromogranin A producing 12 Serotonin producing 6 Gastrin producing 1 Prior treatment Surgery 7 Radiotherapy 3 Systemic therapy 6 Somatostatin analog 1 Interferon α 2 Chemotherapy 2 Radioactive lutetium octreotide/metaiodobenzylguanidine 2 Sunitinib 1 No. of metastases SUVmean/max Tumor location Functional NET CT PET % Baseline 2 wk 12 wk Treatment duration (mo) Best change CT target lesions (%) Pancreas* — 82 34 41 10.9 10.3 6.7 21+ −14 Pancreas† — 7 0 0 — — — 1 NA Pancreas — 26 1 4 5.5 5.6 4.8 21+ −7 Pancreas — 1 0 0 — — — 20+ 13 Pancreas — 39 11 31 5.1 4.5 3.6 10 −4 Pancreas — 27 4 15 2.9 2.8 2.7 14+ −9 Pancreas — 3 3 100 4.8 5.9 5.7 12 0 Duodenum Gastrin 16 3 19 3.4 3.2 2.6 6 −5 Lung Serotonin 41 3 7 7.0 7.9 9.1 8 −3 Small bowel† Serotonin 2 0 0 — — — 3 11 Small bowel‡ Serotonin 29 2 7 8.5 8.8 8.8 12 1 Small bowel Serotonin 25 0 0 — — — 12 −19 Unknown Serotonin 15 1 7 10.4 8.6 7.7 18+ −9 Unknown Serotonin 14 1 7 8.6 4.9 2.6 16+ −13
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- PET Imaging of Receptor Tyrosine Kinases in Cancer
- Molecular Imaging in Cancer Drug Development
- 89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma
- Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
- 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease
- Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature
- Predictive factors of response to mTOR inhibitors in neuroendocrine tumours
- Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy
- TGF-{beta} Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
- Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
- 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment